Head-to-head · Cost-Efficiency Index
Andrew Meds vs Claya
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Andrew Meds
Shoppers comparing published monthly rates who are willing to check that the price on the page is the price the checkout charges.
Visit Andrew MedsClaya
Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate.
Visit ClayaThe verdict
Andrew Meds takes it, leading the Cost-Efficiency Index 70 to 69. Andrew Meds publishes $199 semaglutide and $299 tirzepatide on its product pages, then sends every Get Started button to an intake that sells a $99 low-dose program and never offers tirzepatide at all. Claya still earns a C — Cost-first shoppers who want a same-price-any-dose semaglutide plan, for shoppers willing to consider a multi-month prepay to get the advertised rate.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Andrew Meds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Andrew Meds | Claya |
|---|---|---|
| Cost-Efficiency Index | 70/100 | 69/100 |
| Semaglutide / mo | $199/month month-to-month (the intake this page opens sells a $99 low-dose program instead) | $149/mo (all doses, compounded) |
| Tirzepatide / mo | $299/month month-to-month | $199/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $2,388 | $1,788 |
| Tirzepatide / yr (modeled) | $3,588 | $2,388 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #90 | #97 |
Andrew Meds
70/100Where the value is
- Full month-to-month and prepay ladders for both molecules are printed on the product pages, before any intake
- States which pharmacy class fills a prescription — "a 503(A) compounding pharmacy or 503(B) outsourcing facility" — which most sellers at this price leave unsaid
- Names the prescribing practice, with a street address and a direct phone line, in the footer of every page
The tradeoffs
- Three live semaglutide prices disagree: $199 a month on the product page, $99 a month in the intake that page links to, and $149 for a four-week supply in a second funnel
- The tirzepatide page's own funnel offers only semaglutide, so the $299 tirzepatide price cannot be bought through the route the page provides
Claya
69/100Where the value is
- Semaglutide is explicitly 'same price regardless of dosage' at $149/mo, removing dose-tier guesswork
- LegitScript Certified, BBB Accredited, and HIPAA Compliant badges all displayed together
- '$100 off your first month' promo code (100CLAYA) published openly with no intake required to see it
The tradeoffs
- The advertised $149/$199 rates are qualified elsewhere on the same page as available 'with select multi-month plans' — a shopper reading only the 'a month' headline could reasonably assume pure month-to-month billing when a prepay term may be required
- No state coverage list is published anywhere on the public site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.